Peptide regulations The UCompounded drugs containing CJC-1295may pose risk for immunogenicityfor certain routes of administration and may have complexities with regard to for peptide- ....S.In late 2023, theFDAquietly updated its bulk drug substances list for compounding, categorizing 17 popularpeptidesas “Category 2” substances that pose ... Food and Drug Administration (FDA) is increasingly scrutinizing the peptide market, issuing new regulations and enforcement actions that significantly impact the availability and use of these compounds. Recent FDA news reveals a proactive stance on regulating both approved peptide medications and those marketed for research or unapproved uses, particularly focusing on substances like GLP-1 receptor agonists. This evolving regulatory environment means that understanding the FDA's position on peptides is crucial for researchers, healthcare providers, and consumers navigating this complex field2025年8月26日—Some peptides are FDA-approved drugs. Insulin is a peptide hormone, as are GLP-1 agonists (like semaglutide and tirzepatide) and certain growth ....
The FDA has been actively addressing concerns surrounding unapproved peptide drugs and the marketing of peptides for research purposes only (RUO). In late 2024, the agency issued warning letters to entities illegally marketing peptides online for human use, highlighting a significant enforcement trendThe current wave of enforcement is now targeting manufacturers ofpeptides, particularly where the supply chain lacks transparency.. This crackdown extends to substances like semaglutide, tirzepatide, and retatrutide, which are sometimes deceptively labeled for research despite being intended for human consumption. The FDA's concerns also encompass compounded peptide therapies, with new rules aiming to tighten restrictions on the use of bulk substances. Some popular peptides have been categorized as "Category 2" substances, indicating identified safety risks and leading to legal challenges and industry adjustments.
While regulatory scrutiny intensifies for unapproved products, the FDA has also approved a substantial number of peptide medications. As of late 2024, over 100 peptide medications have received FDA approval, treating a range of conditions. Notably, insulin, a vital peptide hormone, is a prime example of an FDA-approved peptide2025年12月23日—The US Food and Drug Administration has approvedNovo Nordisk's once-daily weight-loss pill, making it the first oral glucagon-like peptide .... Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, have gained significant attention for their efficacy in managing diabetes and promoting weight loss. The FDA has approved several of these for specific indications, including oral formulations for weight management. Beyond GLP-1 RAs, the FDA continues to evaluate and approve peptides for various therapeutic areas, including cardiovascular diseases, human immunodeficiency, and central nervous system disorders. The agency also provides guidance for industry on synthetic peptides, detailing characterization of peptide-related impurity profiles for approved products.
The FDA's proactive approach also involves ongoing safety evaluations of approved peptide medications.2026年1月13日—TheFDAhas issued new information about glucagon-likepeptide-1 receptor agonists (GLP-1 RAs). See theFDADrug Safety Communication issued ... For instance, the agency has been evaluating reports of suicidal behavior and ideation associated with GLP-1 RA medications, though recent updates indicate a potential removal of this warning from certain GLP-1 RAs. Another area of focus is immunogenicity, the potential for the body to mount an immune response against a drugIn this Ground Truths post I'll review them by 2 categories: (1) thepeptides that have been FDA approvedbut are getting extensive off-label .... The FDA is reopening comment periods on the immunogenicity risks of host cell proteins in follow-on recombinant peptide products and has published insights on immunogenicity risks related to peptide-related impurities in generic teriparatide2025年11月15日—The FDA has approved a number of peptides as medications, including insulin for diabetics who don't naturally produce it and human growth .... These evaluations underscore the FDA's commitment to ensuring the safety and efficacy of peptide-based therapeutics.
The landscape of peptide development and regulation is dynamic. The FDA's increasing oversight, including the establishment of import alerts like the "green list" to prevent dangerous GLP-1 products, signals a continued commitment to safeguarding public health2024年12月18日—The US Food and Drug Administration (FDA) has issued warning letters to four companies sellingunapproved glucagon-likepeptide-1 receptor agonist (GLP-1RA) .... As more peptide drugs, including novel TIDES (peptides and oligonucleotides), emerge and gain FDA approval, understanding the regulatory framework, approved indications, and potential risks will remain paramountA closer look at the unapproved peptide injections .... The agency's actions, from enforcement against unapproved products to detailed safety assessments of approved medications, shape the future of peptide research, development, and patient access.
Join the newsletter to receive news, updates, new products and freebies in your inbox.